MetaADEDB 2.0 @ LMMD
Norethindrone
(VIKNJXKGJWUCNN-XGXHKTLJSA-N)
Structure
SMILES
C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12
Type(s)
Approved
ATC code(s)
G03AA05; G03AB04; G03AC01; G03DC02; G03FA01; G03FB05
Molecular Formula:
C20H26O2
Molecular Weight:
298.419
Log P:
3.4925
Hydrogen Bond Acceptor:
2
Hydrogen Bond Donor:
1
TPSA:
37.3
CAS Number(s):
68-22-4
Synonym(s)
1.
Norethindrone
2.
Ethinylnortestosterone
3.
Norethisterone
4.
Norpregneninolone
5.
Conceplan
6.
Micronor
7.
Monogest
8.
Nor-QD
9.
Norcolut
10.
Norcolute
11.
Norethindrone, (1 beta)-Isomer
12.
Norlutin
13.
Nor QD
14.
NorQD
External Link(s)
MeSHD009640
PubChem Compound6230
BindingDB50148732
ChEBI7627
CHEMBLCHEMBL1162
DrugBankDB00717
DrugCentral1962
IUPHAR/BPS Guide to PHARMACOLOGY2880
KEGGcpd:C05028
dr:D00182
Therapeutic Target DatabaseD0GL7U
ZINC85205451
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1No adverse eventFAERS: 270US FAERS
2Drug dose omissionFAERS: 176OFFSIDES
US FAERS
3Product adhesion issueFAERS: 150US FAERS
4Wrong technique in product usage processFAERS: 132US FAERS
5Product quality issueFAERS: 114OFFSIDES
US FAERS
6Drug ineffectiveFAERS: 88
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
7Application site erythemaFAERS: 82US FAERS
8Application site pruritusFAERS: 80US FAERS
9Inappropriate schedule of drug administrationFAERS: 62OFFSIDES
US FAERS
10Therapy cessationFAERS: 57US FAERS
11HeadacheFAERS: 45
Canada Vigilance: 7
9678128
19443681
CTD
SIDER
Canada Vigilance
US FAERS
12Application site irritationFAERS: 42US FAERS
13Pregnancy on oral contraceptiveFAERS: 42
Canada Vigilance: 11
Canada Vigilance
OFFSIDES
US FAERS
14Drug administration errorFAERS: 39US FAERS
15Product storage errorFAERS: 38US FAERS
16Drug exposure during pregnancyFAERS: 36OFFSIDES
US FAERS
17Incorrect product storageFAERS: 36US FAERS
18MetrorrhagiaFAERS: 35SIDER
US FAERS
19Drug prescribing errorFAERS: 32US FAERS
20Night sweatsFAERS: 31US FAERS
21DizzinessFAERS: 30
Canada Vigilance: 5
Canada Vigilance
SIDER
US FAERS
22NauseaFAERS: 30
Canada Vigilance: 4
9678128
19443681
CTD
OFFSIDES
SIDER
Canada Vigilance
US FAERS
23Application site rashFAERS: 26US FAERS
24Drug administered at inappropriate siteFAERS: 25US FAERS
25Abdominal PainFAERS: 24OFFSIDES
SIDER
US FAERS
26Application site painFAERS: 23US FAERS
27FatigueFAERS: 22
Canada Vigilance: 2
19443681CTD
OFFSIDES
SIDER
Canada Vigilance
US FAERS
28Breast tendernessFAERS: 18
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
29Incorrect drug administration durationFAERS: 18US FAERS
30Weight decreasedFAERS: 18
Canada Vigilance: 15
Canada Vigilance
US FAERS
31PalpitationsFAERS: 17US FAERS
32Feeling abnormalFAERS: 16
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
33MalaiseFAERS: 16US FAERS
34NervousnessFAERS: 15SIDER
US FAERS
35Suppressed lactationFAERS: 15
Canada Vigilance: 48
Canada Vigilance
OFFSIDES
SIDER
US FAERS
36AstheniaFAERS: 13
Canada Vigilance: 2
Canada Vigilance
OFFSIDES
SIDER
US FAERS
37ErythemaFAERS: 13US FAERS
38Mood swingsFAERS: 13SIDER
US FAERS
39PruritusFAERS: 1315728406CTD
SIDER
US FAERS
40Application site urticariaFAERS: 12US FAERS
41Drug exposure via breast milkFAERS: 12OFFSIDES
US FAERS
42MenorrhagiaFAERS: 12
Canada Vigilance: 3
19016686CTD
SIDER
Canada Vigilance
US FAERS
43AlopeciaFAERS: 11OFFSIDES
SIDER
US FAERS
44AnxietyFAERS: 11OFFSIDES
US FAERS
45Depressed moodFAERS: 10
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
46Drug dispensing errorFAERS: 10US FAERS
47Drug withdrawal syndromeFAERS: 10US FAERS
48Exposure during breast feedingFAERS: 10US FAERS
49Hormone level abnormalFAERS: 10OFFSIDES
US FAERS
50HypersensitivityFAERS: 10SIDER
US FAERS
51Product administered at inappropriate siteFAERS: 10US FAERS
52SyncopeFAERS: 10
Canada Vigilance: 2
Canada Vigilance
US FAERS
53Adverse eventFAERS: 9OFFSIDES
US FAERS
54Back PainFAERS: 9
Canada Vigilance: 1
Canada Vigilance
US FAERS
55Peripheral swellingFAERS: 9US FAERS
56Pharmaceutical product complaintFAERS: 9US FAERS
57Product use issueFAERS: 9US FAERS
58Skin irritationFAERS: 9US FAERS
59UrticariaFAERS: 9
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
60Application site burnFAERS: 8US FAERS
61Application site exfoliationFAERS: 8US FAERS
62Application site reactionFAERS: 8US FAERS
63Application site vesiclesFAERS: 8US FAERS
64Chest PainFAERS: 8
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
65Medication ErrorFAERS: 8US FAERS
66Therapeutic response unexpectedFAERS: 8US FAERS
67Cerebrovascular accidentFAERS: 7US FAERS
68CryingFAERS: 7
Canada Vigilance: 1
Canada Vigilance
US FAERS
69DehydrationFAERS: 7
Canada Vigilance: 1
Canada Vigilance
US FAERS
70Emotional disorderFAERS: 7OFFSIDES
US FAERS
71Product use in unapproved indicationFAERS: 7US FAERS
72Pulmonary EmbolismFAERS: 7820501CTD
SIDER
US FAERS
73Uterine spasmFAERS: 7OFFSIDES
US FAERS
74AcneFAERS: 6SIDER
US FAERS
75Application site swellingFAERS: 6US FAERS
76ConstipationFAERS: 6US FAERS
77Ectopic PregnancyFAERS: 6US FAERS
78Skin reactionFAERS: 6US FAERS
79Vulvovaginal drynessFAERS: 6
Canada Vigilance: 1
Canada Vigilance
US FAERS
80Abdominal discomfortFAERS: 5
Canada Vigilance: 1
Canada Vigilance
US FAERS
81Application site drynessFAERS: 5US FAERS
82Application site hypersensitivityFAERS: 5US FAERS
83Deep Vein ThrombosisFAERS: 5SIDER
US FAERS
84Mental impairmentFAERS: 5OFFSIDES
US FAERS
85PainFAERS: 5OFFSIDES
US FAERS
86Product dose omissionFAERS: 5
Canada Vigilance: 2
Canada Vigilance
US FAERS
87Product substitution issueFAERS: 5
Canada Vigilance: 1
Canada Vigilance
US FAERS
88SomnolenceFAERS: 5SIDER
US FAERS
89TinnitusFAERS: 5US FAERS
90VomitingFAERS: 5SIDER
US FAERS
91Wrong technique in drug usage processFAERS: 5US FAERS
92Accidental drug intake by childFAERS: 4US FAERS
93AgitationFAERS: 4US FAERS
94Application site erosionFAERS: 4US FAERS
95Application site inflammationFAERS: 4US FAERS
96ArthralgiaFAERS: 4US FAERS
97BronchitisFAERS: 4OFFSIDES
US FAERS
98ChillsFAERS: 4US FAERS
99DiscomfortFAERS: 4US FAERS
100DyspepsiaFAERS: 419443681CTD
SIDER
US FAERS
101Electrolyte depletionFAERS: 4US FAERS
102Expired product administeredFAERS: 4US FAERS
103HypotensionFAERS: 4US FAERS
104Maternal exposure during pregnancyFAERS: 4US FAERS
105PneumoniaFAERS: 4US FAERS
106Premenstrual syndromeFAERS: 4US FAERS
107Prescribed underdoseFAERS: 4US FAERS
108Skin UlcerFAERS: 4US FAERS
109ThrombophlebitisFAERS: 4SIDER
US FAERS
110jaundiceFAERS: 4US FAERS
111Accidental exposure to productFAERS: 3US FAERS
112AmnesiaFAERS: 3OFFSIDES
US FAERS
113Application site warmthFAERS: 3US FAERS
114BronchiectasisFAERS: 3US FAERS
115Chest discomfortFAERS: 3US FAERS
116ChromaturiaFAERS: 3US FAERS
117Circumstance or information capable of leading to medication errorFAERS: 3OFFSIDES
US FAERS
118Emotional distressFAERS: 3US FAERS
119EpistaxisFAERS: 3US FAERS
120EscharFAERS: 3US FAERS
121General physical health deteriorationFAERS: 3OFFSIDES
US FAERS
122Incorrect dose administeredFAERS: 3US FAERS
123Joint swellingFAERS: 3US FAERS
124LacerationFAERS: 3US FAERS
125Mass excisionFAERS: 3US FAERS
126Myocardial InfarctionFAERS: 3SIDER
US FAERS
127Pelvic PainFAERS: 3
Canada Vigilance: 1
Canada Vigilance
US FAERS
128Pharmaceutical product counterfeitFAERS: 3OFFSIDES
US FAERS
129Product packaging issueFAERS: 3US FAERS
130Productive CoughFAERS: 3US FAERS
131Pulmonary FibrosisFAERS: 3US FAERS
132RestlessnessFAERS: 3US FAERS
133Skin necrosisFAERS: 3US FAERS
134SwellingFAERS: 3US FAERS
135Urinary tract infectionFAERS: 3US FAERS
136VertigoFAERS: 3US FAERS
137Accidental exposure to product by childFAERS: 2US FAERS
138Alanine Aminotransferase IncreasedFAERS: 2OFFSIDES
US FAERS
139AngerFAERS: 2OFFSIDES
US FAERS
140AngioedemaFAERS: 2US FAERS
141Ankle FractureFAERS: 2US FAERS
142Application site ulcerFAERS: 2US FAERS
143Arterial thrombosisFAERS: 2US FAERS
144Aspartate Aminotransferase IncreasedFAERS: 2US FAERS
145Autoimmune hepatitisFAERS: 2US FAERS
146AutophobiaFAERS: 2US FAERS
147BiopsyFAERS: 2US FAERS
148BlindnessFAERS: 2SIDER
US FAERS
149Blood cholesterol increasedFAERS: 2US FAERS
150Blood glucose decreasedFAERS: 2OFFSIDES
US FAERS
151Blood potassium decreasedFAERS: 2US FAERS
152Blood triglycerides increasedFAERS: 2OFFSIDES
US FAERS
153Breast CystFAERS: 2US FAERS
154Carpal Tunnel SyndromeFAERS: 2US FAERS
155Cataract operationFAERS: 2OFFSIDES
US FAERS
156Cholecystitis infectiveFAERS: 2US FAERS
157CholelithiasisFAERS: 2US FAERS
158Completed SuicideFAERS: 2US FAERS
159CystitisFAERS: 2US FAERS
160CystFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
161DeafnessFAERS: 2US FAERS
162Depression suicidalFAERS: 2US FAERS
163DisabilityFAERS: 2US FAERS
164Dry skinFAERS: 2US FAERS
165EpilepsyFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
166Failure to ThriveFAERS: 2US FAERS
167Feeling of body temperature changeFAERS: 2US FAERS
168FlatulenceFAERS: 2SIDER
US FAERS
169Head discomfortFAERS: 2US FAERS
170HemiparesisFAERS: 2OFFSIDES
US FAERS
171Hypertensive crisisFAERS: 2US FAERS
172HypothyroidismFAERS: 2US FAERS
173Impaired work abilityFAERS: 2US FAERS
174Inappropriate schedule of product administrationFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
175InfluenzaFAERS: 2US FAERS
176Intentional dose omissionFAERS: 2US FAERS
177Intentional self-injuryFAERS: 2OFFSIDES
US FAERS
178Lactation DisorderFAERS: 2
Canada Vigilance: 4
Canada Vigilance
US FAERS
179Lactose IntoleranceFAERS: 2OFFSIDES
US FAERS
180Lip and/or oral cavity cancerFAERS: 2US FAERS
181MyalgiaFAERS: 2US FAERS
182NasopharyngitisFAERS: 2US FAERS
183Oropharyngeal painFAERS: 2US FAERS
184PapuleFAERS: 2US FAERS
185ParanoiaFAERS: 2US FAERS
186PemphigusFAERS: 2US FAERS
187Pregnancy on contraceptiveFAERS: 2US FAERS
188PregnancyFAERS: 2SIDER
US FAERS
189Prescribed overdoseFAERS: 2US FAERS
190Product dosage form confusionFAERS: 2US FAERS
191Product packaging quantity issueFAERS: 2US FAERS
192Renal painFAERS: 2US FAERS
193RetchingFAERS: 2US FAERS
194RosaceaFAERS: 2US FAERS
195TachycardiaFAERS: 2US FAERS
196Therapeutic product contaminationFAERS: 2US FAERS
197Therapeutic product ineffectiveFAERS: 2US FAERS
198ThrombosisFAERS: 2SIDER
US FAERS
199Tooth InfectionFAERS: 2US FAERS
200TremorFAERS: 2US FAERS
201Violence-related symptomFAERS: 2OFFSIDES
US FAERS
202furuncleFAERS: 2US FAERS
203AbasiaFAERS: 1US FAERS
204Abdominal massFAERS: 1US FAERS
205Abdominal rigidityFAERS: 1US FAERS
206Accidental exposureFAERS: 1US FAERS
207Activities of daily living impairedFAERS: 1OFFSIDES
US FAERS
208Adnexa uteri painFAERS: 1US FAERS
209AgoraphobiaFAERS: 1US FAERS
210AneurysmFAERS: 1US FAERS
211AnhedoniaFAERS: 1US FAERS
212AnorexiaFAERS: 1US FAERS
213Application site discomfortFAERS: 1US FAERS
214Application site eczemaFAERS: 1US FAERS
215Application site lacerationFAERS: 1US FAERS
216Application site noduleFAERS: 1US FAERS
217Application site scarFAERS: 1US FAERS
218Arthropod biteFAERS: 1US FAERS
219Atrial FibrillationFAERS: 1US FAERS
220Axillary vein thrombosisFAERS: 1US FAERS
221Bile acid malabsorptionFAERS: 1US FAERS
222Blood alkaline phosphatase increasedFAERS: 1OFFSIDES
US FAERS
223Blood count abnormalFAERS: 1US FAERS
224Blood glucose increasedFAERS: 1US FAERS
225Bone painFAERS: 1US FAERS
226Breast FeedingFAERS: 1
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
227Breast cancer stage IIFAERS: 1US FAERS
228Burning sensationFAERS: 1US FAERS
229Cardiac discomfortFAERS: 1US FAERS
230Cerebral InfarctionFAERS: 1US FAERS
231ChloasmaFAERS: 1SIDER
US FAERS
232ChokingFAERS: 1US FAERS
233CholestasisFAERS: 17100632
15728406
CTD
US FAERS
234Cold sweatFAERS: 1US FAERS
235Complications of maternal exposure to therapeutic drugsFAERS: 1US FAERS
236Corneal abscessFAERS: 1US FAERS
237Dark circles under eyesFAERS: 1US FAERS
238DementiaFAERS: 1US FAERS
239Device defectiveFAERS: 1US FAERS
240Device leakageFAERS: 1US FAERS
241DiplopiaFAERS: 1US FAERS
242Disease ProgressionFAERS: 1US FAERS
243Disease recurrenceFAERS: 1US FAERS
244DisorientationFAERS: 1US FAERS
245DissociationFAERS: 1US FAERS
246Drug administered to patient of inappropriate ageFAERS: 1US FAERS
247Drug ineffective for unapproved indicationFAERS: 1US FAERS
248DysarthriaFAERS: 1US FAERS
249DysgeusiaFAERS: 1US FAERS
250DyspareuniaFAERS: 1OFFSIDES
US FAERS
251EczemaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
252Ejection Fraction DecreasedFAERS: 1US FAERS
253Embolic strokeFAERS: 1US FAERS
254EmbolismFAERS: 1
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
255Endometrial adenocarcinomaFAERS: 1US FAERS
256Epinephrine increasedFAERS: 1US FAERS
257EpiscleritisFAERS: 1US FAERS
258Erythema NodosumFAERS: 1
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
259Exposure via breast milkFAERS: 1
Canada Vigilance: 4
Canada Vigilance
US FAERS
260Eye irritationFAERS: 1US FAERS
261Facial paralysisFAERS: 1US FAERS
262Feeling ColdFAERS: 1OFFSIDES
US FAERS
263Feeling jitteryFAERS: 1US FAERS
264Fibrin D dimer increasedFAERS: 1US FAERS
265Food cravingFAERS: 1
Canada Vigilance: 1
Canada Vigilance
OFFSIDES
US FAERS
266Gene MutationFAERS: 1US FAERS
267Heavy exposure to ultraviolet lightFAERS: 1US FAERS
268Hepatic InfarctionFAERS: 1US FAERS
269HostilityFAERS: 1US FAERS
270HyperplasiaFAERS: 1US FAERS
271HypertrichosisFAERS: 1US FAERS
272HyperventilationFAERS: 1US FAERS
273HypokinesiaFAERS: 1US FAERS
274HysterectomyFAERS: 1US FAERS
275Impaired driving abilityFAERS: 1US FAERS
276Injection Site ReactionFAERS: 1US FAERS
277Intentional product misuseFAERS: 1US FAERS
278Intentional product use issueFAERS: 1US FAERS
279Intercepted drug dispensing errorFAERS: 1US FAERS
280LethargyFAERS: 1US FAERS
281LeukopeniaFAERS: 1US FAERS
282Macular degenerationFAERS: 1US FAERS
283Malignant breast lump removalFAERS: 1US FAERS
284Malignant tumour excisionFAERS: 1US FAERS
285MastectomyFAERS: 1OFFSIDES
US FAERS
286MastitisFAERS: 1US FAERS
287Maternal exposure during breast feedingFAERS: 1US FAERS
288Memory impairmentFAERS: 1US FAERS
289MoaningFAERS: 1US FAERS
290Multiple SclerosisFAERS: 1OFFSIDES
US FAERS
291Muscle RigidityFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
292Musculoskeletal chest painFAERS: 1US FAERS
293Musculoskeletal stiffnessFAERS: 1OFFSIDES
US FAERS
294MyelofibrosisFAERS: 1US FAERS
295Nipple painFAERS: 1US FAERS
296Obesity surgeryFAERS: 1US FAERS
297Ocular icterusFAERS: 1US FAERS
298Oral painFAERS: 1US FAERS
299Oropharyngeal blisteringFAERS: 1US FAERS
300OsteopeniaFAERS: 1OFFSIDES
US FAERS
301Ovarian adenomaFAERS: 1US FAERS
302Packaging design issueFAERS: 1US FAERS
303Panic DisorderFAERS: 1US FAERS
304PetechiaeFAERS: 1US FAERS
305Portal Vein ThrombosisFAERS: 1US FAERS
306Pregnancy test positiveFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
307PresyncopeFAERS: 1US FAERS
308Product administration errorFAERS: 1US FAERS
309Product contaminationFAERS: 1US FAERS
310Product identification number issueFAERS: 1US FAERS
311Product label confusionFAERS: 1US FAERS
312Product label issueFAERS: 1US FAERS
313Product measured potency issueFAERS: 1US FAERS
314Psychological TraumaFAERS: 1US FAERS
315Rash erythematousFAERS: 1US FAERS
316SalpingitisFAERS: 1US FAERS
317SchizophreniaFAERS: 1US FAERS
318ScreamingFAERS: 1US FAERS
319SinusitisFAERS: 1US FAERS
320Skin ErosionFAERS: 1US FAERS
321Skin lesionFAERS: 1US FAERS
322SluggishnessFAERS: 1US FAERS
323Spina BifidaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
324Splenic InfarctionFAERS: 1US FAERS
325SplenomegalyFAERS: 1US FAERS
326TensionFAERS: 1SIDER
US FAERS
327ThirstFAERS: 1US FAERS
328Thyroid hormones decreasedFAERS: 1US FAERS
329Tongue blisteringFAERS: 1US FAERS
330TonsillitisFAERS: 1US FAERS
331Tooth ExtractionFAERS: 1US FAERS
332TrichorrhexisFAERS: 1US FAERS
333Ultrasound liver abnormalFAERS: 1US FAERS
334UnderweightFAERS: 1US FAERS
335Unevaluable eventFAERS: 1US FAERS
336Urinary IncontinenceFAERS: 1US FAERS
337Uterine PolypFAERS: 1OFFSIDES
US FAERS
338Vaginal DischargeFAERS: 1US FAERS
339Vitamin D DeficiencyFAERS: 1US FAERS
340Wrong drug administeredFAERS: 1US FAERS
341YawningFAERS: 1US FAERS
342Abdominal CrampsSIDER
343Abdominal bloatingSIDER
344Abnormal cervical smearOFFSIDES
345Abnormal visionOFFSIDES
346Acne Vulgaris8222658CTD
347Activated Protein C Resistance15333036CTD
348Acute Coronary SyndromeSIDER
349AdenocarcinomaOFFSIDES
350Adenoma204807
3105752
CTD
351AgeusiaOFFSIDES
352Alanine aminotransferase abnormalOFFSIDES
353Allergic rashSIDER
354Allergy test positiveOFFSIDES
355Anaphylactic shockSIDER
356Anaphylactoid ReactionSIDER
357AnhidrosisOFFSIDES
358Anorectal discomfortOFFSIDES
359AnosmiaOFFSIDES
360AnovulationSIDER
361ApathyOFFSIDES
362Apparent deathOFFSIDES
363Arterial thromboembolismSIDER
364ArthritisOFFSIDES
365ArthropathyOFFSIDES
366ArthroscopyOFFSIDES
367Aspartate aminotransferase abnormalOFFSIDES
368AspergillosisOFFSIDES
369Atrial septal defect 2830309CTD
370AuraOFFSIDES
371Autoimmune thyroiditisOFFSIDES
372Bed restOFFSIDES
373Biopsy breast abnormalOFFSIDES
374Biopsy site unspecified abnormalOFFSIDES
375Blood GlucoseOFFSIDES
376Blood thyroid stimulating hormone increasedOFFSIDES
377Bone Diseases4416533CTD
378Carbohydrate tolerance decreasedSIDER
379CarcinomaSIDER
380Cardiac perforationOFFSIDES
381Cardiovascular Diseases87143CTD
382CellulitisOFFSIDES
383Cerebral ThrombosisSIDER
384Choking sensationOFFSIDES
385Cholestasis of pregnancyOFFSIDES
386Chronic Obstructive Airway DiseaseOFFSIDES
387ConfabulationOFFSIDES
388DemyelinationOFFSIDES
389Dermatitis hemorrhagicSIDER
390DermatitisSIDER
391Dextrocardia4416533CTD
392Diabetic FootOFFSIDES
393Diabetic NephropathyOFFSIDES
394Diarrhea19443681CTD
OFFSIDES
395Dilatation intrahepatic duct acquiredOFFSIDES
396Disorders of Sex Development4416533CTD
397Double Outlet Right Ventricle830309CTD
398DrowsinessOFFSIDES
SIDER
399Drug addictOFFSIDES
400Drug level changedOFFSIDES
401Drug withdrawal headacheOFFSIDES
402DysmenorrheaOFFSIDES
403DysphemiaOFFSIDES
404Ebstein Anomaly830309CTD
405EnuresisOFFSIDES
406Enzyme abnormalityOFFSIDES
407EpiglottitisOFFSIDES
408Erythema MultiformeSIDER
409Euphoric moodOFFSIDES
410Feeding and Eating Disorders19443681CTD
411FibromyalgiaOFFSIDES
412FormicationOFFSIDES
413FrustrationOFFSIDES
414Gastrointestinal PainSIDER
415Genital dischargeSIDER
416GlobulinuriaOFFSIDES
417Hepatic Veno-Occlusive Disease9845522CTD
418HepatitisSIDER
419HepatotoxicityOFFSIDES
420HirsutismSIDER
421HungerCanada Vigilance: 1Canada Vigilance
422HypophagiaCanada Vigilance: 2Canada Vigilance
423Incorrect product administration durationCanada Vigilance: 1Canada Vigilance
424Infantile ColicCanada Vigilance: 1Canada Vigilance
425InfertilitySIDER
426Inhibitory drug interactionOFFSIDES
427Injection site erythemaOFFSIDES
428Injection site noduleOFFSIDES
429Jaundice, Obstructive5639192
15728406
CTD
430Kidney FailureOFFSIDES
431Labile hypertensionOFFSIDES
432Lack of satietyCanada Vigilance: 1Canada Vigilance
433Leukopenia neonatalOFFSIDES
434Live BirthOFFSIDES
435Liver neoplasms204807
3105752
25058030
CTD
436Low density lipoprotein increasedSIDER
437Lupus-like syndromeOFFSIDES
438LymphangitisOFFSIDES
439LymphedemaOFFSIDES
440MacrognathiaOFFSIDES
441Meniscus operationOFFSIDES
442Mesenteric Vascular Occlusion4121539CTD
443Micturition frequency decreasedCanada Vigilance: 1Canada Vigilance
444Middle insomniaOFFSIDES
445Monoclonal Gammopathy of Undetermined Significance820501CTD
446Mononucleosis syndromeOFFSIDES
447Morbid thoughtsOFFSIDES
448Movement Disorders5354812CTD
449Muscle WeaknessOFFSIDES
450Muscle tightnessOFFSIDES
451MyopiaOFFSIDES
452Nervous tensionOFFSIDES
453NeurilemmomaOFFSIDES
454NeurodermatitisOFFSIDES
455Nicotine DependenceOFFSIDES
456Optic NeuritisOFFSIDES
SIDER
457Partner stressOFFSIDES
458Personality change due to a general medical conditionOFFSIDES
459Physical breast examination abnormalOFFSIDES
460Physical examination abnormalOFFSIDES
461Poor feeding infantCanada Vigilance: 1Canada Vigilance
462Poor quality sleepCanada Vigilance: 1Canada Vigilance
463Post procedural complicationOFFSIDES
464Post procedural infectionOFFSIDES
465Postmenopausal bleedingOFFSIDES
466Pregnancy with contraceptive deviceCanada Vigilance: 1Canada Vigilance
467Progesterone receptor assayOFFSIDES
468PrurigoSIDER
469Pseudotumor Cerebri6805652CTD
470Psychiatric symptomOFFSIDES
471PurpuraSIDER
472Restrictive pulmonary diseaseOFFSIDES
473Retinal vascular thrombosisSIDER
474Right atrial dilatationOFFSIDES
475Scan lymph nodesOFFSIDES
476SeromaOFFSIDES
477Sexually activeSIDER
478Skin IndurationOFFSIDES
479Sleep TalkingOFFSIDES
480Spasm5784655CTD
481StressOFFSIDES
482StridorOFFSIDES
483Synovial CystOFFSIDES
484Taste Disorders19443681CTD
485Temperature intoleranceOFFSIDES
486Therapeutic procedureOFFSIDES
487Thyroid cancer metastaticOFFSIDES
488Tobacco userOFFSIDES
489Tongue eruptionOFFSIDES
490Ultrasound breast abnormalOFFSIDES
491Unspecified visual lossSIDER
492Venoocclusive diseaseOFFSIDES
493Venous Thromboembolism19016686CTD
494Ventricular FibrillationOFFSIDES
495Vitamin A DeficiencyOFFSIDES
496Vocal Cord ParalysisOFFSIDES
497Vulvovaginal adhesionOFFSIDES
498Vulvovaginal burning sensationOFFSIDES
499Weight Gain8222658CTD
OFFSIDES
500Weight decrease neonatalCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120235

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.